Boston Scientific Corporation $BSX Position Lowered by Redmile Group LLC

Key Points

• Redmile Group LLC has reduced its stake in Boston Scientific Corporation by 38.2%, now holding approximately $19.50 million worth of shares.
• Insider trading activity showed significant sales, with Director Yoshiaki Fujimori and EVP Arthur C. Butcher selling a combined total of 20,214 shares, indicating a potential decrease in confidence from company executives.
• Boston Scientific reported a 22.8% increase in year-over-year revenue, with earnings per share beating analysts' estimates, showcasing strong financial performance despite recent stock movements.

Redmile Group LLC decreased its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 38.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 193,283 shares of the medical equipment provider's stock after selling 119,400 shares during the period. Boston Scientific makes up about 1.8% of Redmile Group LLC's holdings, making the stock its 17th biggest position. Redmile Group LLC's holdings in Boston Scientific were worth $19,498,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of Boston Scientific by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock worth $13,577,311,000 after acquiring an additional 1,697,945 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in shares of Boston Scientific by 2.5% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 22,312,967 shares of the medical equipment provider's stock worth $1,992,994,000 after acquiring an additional 554,388 shares during the period. Invesco Ltd. grew its holdings in shares of Boston Scientific by 5.3% in the 1st quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider's stock worth $1,677,124,000 after acquiring an additional 834,274 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Boston Scientific by 10.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider's stock worth $1,426,779,000 after acquiring an additional 1,383,524 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Boston Scientific by 18.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,839,362 shares of the medical equipment provider's stock worth $968,172,000 after acquiring an additional 1,709,461 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Down 0.1%

Shares of NYSE:BSX traded down $0.15 during mid-day trading on Friday, hitting $107.14. 4,062,436 shares of the company traded hands, compared to its average volume of 5,787,252. The firm has a market cap of $158.76 billion, a P/E ratio of 63.78, a PEG ratio of 2.58 and a beta of 0.65. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $108.94. The firm's 50 day simple moving average is $104.77 and its 200 day simple moving average is $102.20. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's quarterly revenue was up 22.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company's stock, valued at $2,469,268. This represents a 42.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 174,214 shares of company stock valued at $18,397,457. Corporate insiders own 0.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on BSX shares. Morgan Stanley upped their price target on Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a report on Friday, May 16th. Wells Fargo & Company upped their target price on Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Citigroup reaffirmed a "buy" rating and issued a $125.00 target price (up previously from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Leerink Partners assumed coverage on Boston Scientific in a research note on Monday, June 16th. They issued an "outperform" rating and a $118.00 target price on the stock. Finally, Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $117.50.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.